Treatment Options in Smoking Cessation: What Place for Bupropion Sustained-Release?

Bupropion SR is approved for the treatment of tobacco dependence in adult smokers. Bupropion SR is an atypical antidepressant that has been shown to double the likelihood of quitting smoking (to roughly 19%-24% six months into a quit attempt), perhaps by acting on dopaminergic and noradrenergic systems and by acting as an antagonist of nicotine acetylcholine receptors. Head-to-head comparisons of bupropion SR and other stop-smoking treatments suggest that bupropion SR is as or more efficacious than nicotine replacement therapies, equally efficacious as nortriptyline, and less efficacious than varenicline. The evidence available regarding the effectiveness of bupropion SR in real-world settings suggests that abstinence rates are similar to those seen in controlled clinical trials. Bupropion SR appears to be safe and efficacious for both men and women and for people with comorbid medical or mental health conditions. Evidence collected to date supports the use of bupropion SR as a safe, tolerable pharmacotherapy for smoking cessation among adult smokers without a predisposition to seizures, but also suggests that benefits in terms of abstinence last only as long as treatment continues. This review focuses on recent evidence regarding bupropion SR effects and highlights important questions regarding the duration of effects, relative efficacy, effectiveness in clinical use, mechanisms of action, and utilization of bupropion SR that remain unanswered.

[1]  Timothy B Baker,et al.  Psychological mediators of bupropion sustained-release treatment for smoking cessation. , 2008, Addiction.

[2]  L. Epstein,et al.  Toward Personalized Therapy for Smoking Cessation: A Randomized Placebo‐controlled Trial of Bupropion , 2008, Clinical pharmacology and therapeutics.

[3]  J. O'Loughlin,et al.  Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials , 2008, Canadian Medical Association Journal.

[4]  P. Jatlow,et al.  A Placebo-Controlled Trial of Bupropion Combined with Nicotine Patch for Smoking Cessation in Schizophrenia , 2008, Biological Psychiatry.

[5]  Saul Shiffman,et al.  A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. , 2008, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[6]  L. Epstein,et al.  Can the blind see? Participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation. , 2008, Journal of substance abuse treatment.

[7]  W. Hall,et al.  Australian smokers' use of bupropion and nicotine replacement therapies and their relation to reimbursement, Australia 2001-05. , 2008, Drug and alcohol review.

[8]  D. Mackinnon.  Introduction to Statistical Mediation Analysis , 2008 .

[9]  Megan E. Piper,et al.  Using mediational models to explore the nature of tobacco motivation and tobacco treatment effects. , 2006, Journal of abnormal psychology.

[10]  Joseph C. Cappelleri,et al.  Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt , 2008, Psychopharmacology.

[11]  D. Sherrill,et al.  Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation. , 2007, Archives of pediatrics & adolescent medicine.

[12]  Anna M. Lee,et al.  CYP2B6 Genotype Alters Abstinence Rates in a Bupropion Smoking Cessation Trial , 2007, Biological Psychiatry.

[13]  C. la Vecchia,et al.  A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. , 2007, Archives of internal medicine.

[14]  Megan E. Piper,et al.  Efficacy of bupropion alone and in combination with nicotine gum. , 2007, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[15]  H. Jiang,et al.  A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. , 2007, Addiction.

[16]  Richard A. Brown,et al.  Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. , 2007, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[17]  D. Goff,et al.  A 12-Week Double-Blind, Placebo-Controlled Study of Bupropion SR Added to High-Dose Dual Nicotine Replacement Therapy for Smoking Cessation or Reduction in Schizophrenia , 2007, Journal of clinical psychopharmacology.

[18]  Lynette M. Smith,et al.  Bupropion and nicotine patch as smoking cessation aids in alcoholics. , 2007, Alcohol.

[19]  A. Abrantes,et al.  Bupropion and cognitive-behavioral treatment for depression in smoking cessation. , 2007, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[20]  A. Lanto,et al.  Effectiveness of an On-Call Counselor at Increasing Smoking Treatment , 2007, Journal of General Internal Medicine.

[21]  G. Swan,et al.  Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. , 2007, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[22]  A. Stotts,et al.  Adding MEMS feedback to behavioral smoking cessation therapy increases compliance with bupropion: a replication and extension study. , 2007, Addictive Behaviours.

[23]  R. Hurt,et al.  Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. , 2007, Mayo Clinic proceedings.

[24]  L. Epstein,et al.  Catechol-O-Methyltransferase (COMT) Gene Variants Predict Response to Bupropion Therapy for Tobacco Dependence , 2007, Biological Psychiatry.

[25]  Kumanan Wilson,et al.  Effectiveness of smoking cessation therapies: a systematic review and meta-analysis , 2006, BMC public health.

[26]  R. Anziano,et al.  Long-term fatty fish consumption and renal cell carcinoma incidence in women. , 2006, JAMA.

[27]  Jason Gong,et al.  Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial , 2006 .

[28]  David Gonzales,et al.  Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial , 2006 .

[29]  J. Chatkin,et al.  A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. , 2006, Pulmonary pharmacology & therapeutics.

[30]  A. Schatzberg,et al.  Extended treatment with bupropion SR for cigarette smoking cessation. , 2006, Journal of consulting and clinical psychology.

[31]  J. McCormack,et al.  Outcomes of Bupropion Therapy for Smoking Cessation During Routine Clinical Use , 2006, The Annals of pharmacotherapy.

[32]  M. Henderson,et al.  Pragmatic, observational study of bupropion treatment for smoking cessation in general practice , 2005, Postgraduate Medical Journal.

[33]  E. Wouters,et al.  Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. , 2005, Archives of internal medicine.

[34]  S. Tiffany,et al.  Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h , 2005, Psychopharmacology.

[35]  M. Shoaib,et al.  How does bupropion work as a smoking cessation aid? , 2005, Addiction biology.

[36]  L. Brauer,et al.  Inhibition of CYP2D6 Activity by Bupropion , 2005, Journal of clinical psychopharmacology.

[37]  L. Carrozzi,et al.  Bupropion SR vs placebo for smoking cessation in health care professionals. , 2005, American journal of health behavior.

[38]  Richard A. Brown,et al.  Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. , 2005, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[39]  B. Birmaher,et al.  Steady-state pharmacokinetics of bupropion SR in juvenile patients. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[40]  A. Stotts,et al.  Medication Compliance During a Smoking Cessation Clinical Trial: A Brief Intervention Using MEMS Feedback , 2005, Journal of Behavioral Medicine.

[41]  G. Koren,et al.  Effectiveness of Bupropion for Smoking Cessation During Pregnancy , 2005, Journal of addictive diseases.

[42]  G. Koren,et al.  Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. , 2005, American journal of obstetrics and gynecology.

[43]  S. Fu,et al.  National trends in the provision of smoking cessation aids within the Veterans Health Administration. , 2005, The American journal of managed care.

[44]  A. Jemal,et al.  Under-use of smoking-cessation treatments: results from the National Health Interview Survey, 2000. , 2005, American journal of preventive medicine.

[45]  S. Shiffman,et al.  Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR. , 2004, Addiction.

[46]  E. Hudes,et al.  Bupropion for smoking cessation: a randomized trial. , 2004, Archives of internal medicine.

[47]  R. Walton,et al.  Zyban for smoking cessation in a general practice setting: the response to an invitation to make a quit attempt , 2004, Addiction biology.

[48]  F. Lebargy,et al.  Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. , 2004, Addiction.

[49]  T. Robinson,et al.  Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. , 2004, Journal of consulting and clinical psychology.

[50]  K. Bennett,et al.  Initial uptake and evidence of safe prescribing practice with Buproprion (Zyban®) , 2004, Pharmacoepidemiology and drug safety.

[51]  Richard A. Brown,et al.  Do small lapses predict relapse to smoking behavior under bupropion treatment? , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[52]  S. Holmes,et al.  Bupropion as an aid to smoking cessation: a review of real‐life effectiveness , 2004, International journal of clinical practice.

[53]  J. Vestbo,et al.  A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[54]  N. Rigotti,et al.  Bupropion SR for relapse prevention: a "slips-allowed" analysis. , 2004, American journal of health behavior.

[55]  S. Shakir,et al.  Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000 , 2003, European Journal of Clinical Pharmacology.

[56]  H. Javitz,et al.  Effectiveness of Bupropion Sustained Release for Smoking Cessation in a Health Care Setting: A Randomized Trial , 2003 .

[57]  M. Bergström,et al.  In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography , 2003, Biological Psychiatry.

[58]  L. Epstein,et al.  Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. , 2003, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[59]  S. Tonstad,et al.  A multicentre, randomized, double‐blind, placebo‐controlled, 1‐year study of bupropion SR for smoking cessation , 2003, Journal of internal medicine.

[60]  L. Dwoskin,et al.  Effect of bupropion on nicotine self-administration in rats , 2003, Psychopharmacology.

[61]  R. Richmond,et al.  Review of bupropion for smoking cessation. , 2003, Drug and alcohol review.

[62]  S. Tonstad,et al.  Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. , 2003, European heart journal.

[63]  J. Cryan,et al.  Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat , 2003, Psychopharmacology.

[64]  L. Ferry,et al.  EFFICACY AND SAFETY OF BUPROPION SR FOR SMOKING CESSATION: DATA FROM CLINICAL TRIALS AND FIVE YEARS OF POSTMARKETING EXPERIENCE , 2003, International journal of clinical practice.

[65]  J. Martínez-Raga,et al.  Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile , 2003, Addiction biology.

[66]  R. Hurt,et al.  Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  B. Jamerson,et al.  Targeting smokers at increased risk for relapse: treating women and those with a history of depression. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[68]  S. Hall,et al.  Psychological intervention and antidepressant treatment in smoking cessation. , 2002, Archives of general psychiatry.

[69]  M. Mayo,et al.  Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. , 2002, JAMA.

[70]  L. Epstein,et al.  Mediating mechanisms for the impact of bupropion in smoking cessation treatment. , 2002, Drug and alcohol dependence.

[71]  A. Buist,et al.  Effects of gender on relapse prevention in smokers treated with bupropion SR. , 2002, American journal of preventive medicine.

[72]  M. Fiore,et al.  Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. , 2002, Chest.

[73]  Megan E. Piper,et al.  Gender and racial/ethnic differences in tobacco-dependence treatment: a commentary and research recommendations. , 2001, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[74]  A. Buist,et al.  Sustained-Release Bupropion for Pharmacologic Relapse Prevention after Smoking Cessation , 2001, Annals of Internal Medicine.

[75]  B. Jamerson,et al.  Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: A randomized placebo‐controlled study , 2001, Clinical pharmacology and therapeutics.

[76]  P. Anderson,et al.  Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial , 2001, The Lancet.

[77]  E. D. Glover,et al.  Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. , 2001, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[78]  D. Balfour,et al.  THE PHARMACOLOGY UNDERLYING PHARMACOTHERAPY FOR TOBACCO DEPENDENCE: A FOCUS ON BUPROPION , 2001, International journal of clinical practice.

[79]  M. Damaj,et al.  Bupropion is a nicotinic antagonist. , 2000, The Journal of pharmacology and experimental therapeutics.

[80]  L. Stead,et al.  Anxiolytics and antidepressants for smoking cessation. , 2000, The Cochrane database of systematic reviews.

[81]  S. Shiffman,et al.  The effect of bupropion on nicotine craving and withdrawal , 2000, Psychopharmacology.

[82]  Aker,et al.  A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. , 1999, The New England journal of medicine.

[83]  C. Patten,et al.  Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism∗ , 1999, British Journal of Psychiatry.

[84]  R. Lukas,et al.  Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. , 1999, The Journal of pharmacology and experimental therapeutics.

[85]  S. Preskorn,et al.  Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. , 1998, Journal of Affective Disorders.

[86]  Darrell R. Schroeder,et al.  A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation , 1997 .

[87]  J. A. Johnston,et al.  Pharmacokinetics of Bupropion and its Metabolites in Cigarette Smokers versus Nonsmokers , 1997, Journal of clinical pharmacology.

[88]  J. Feighner,et al.  Bupropion: a review of its mechanism of antidepressant activity. , 1995, The Journal of clinical psychiatry.

[89]  B. Cooper,et al.  Evidence that the Acute Behavioral and Electrophysiological Effects of Bupropion (Wellbutrin®) Are Mediated by a Noradrenergic Mechanism , 1994, Neuropsychopharmacology.

[90]  H. Fibiger,et al.  Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[91]  T. Sharp,et al.  Effect of naloxone-precipitated morphine withdrawal on noradrenaline release in rat hippocampus in vivo. , 1992, European journal of pharmacology.